Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

被引：50

作者：

Sequist, Lecia V. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

来源：

ONCOLOGIST | 2007年 / 12卷 / 03期

关键词：

epidermal growth factor receptor; non-small cell lung cancer; tyrosine kinase;

D O I：

10.1634/theoncologist.12-3-325

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibiting epidermal growth factor receptor ( EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and clinical research within the field. Second-generation EGFR-targeted agents that aim to further improve patient outcomes are now in preclinical and clinical trials. This review discusses four promising agents that are currently being studied in NSCLC: EKB-569, HKI-272, CI-1033, and ZD6474.

引用

页码：325 / 330

页数：6

共 53 条

[1] Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential atmlication for the treatment of breast cancer [J].

Allen, LF ;

Eiseman, IA ;

Fry, DW ;

Lenehan, PF .

SEMINARS IN ONCOLOGY, 2003, 30 (05) :65-78

[2] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[3] Administration of CI-1033, an irreversible Pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: A phase I pharmacokinetic and food effect study [J].

Calvo, E ;

Tolcher, AW ;

Hammond, LA ;

Patnaik, A ;

de Bono, JS ;

Eiseman, IA ;

Olson, SC ;

Lenehan, PF ;

McCreery, H ;

LoRusso, P ;

Rowinsky, EK .

CLINICAL CANCER RESEARCH, 2004, 10 (21) :7112-7120

[4]

Camp ER, 2005, CLIN CANCER RES, V11, P397

[5] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[6]

Ciardiello F, 2003, CLIN CANCER RES, V9, P1546

[7] Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy [J].

Ciardiello, F ;

Bianco, R ;

Caputo, R ;

Damiano, V ;

Troiani, T ;

Melisi, D ;

De Vita, F ;

De Placido, S ;

Bianco, AR ;

Tortora, G .

CLINICAL CANCER RESEARCH, 2004, 10 (02) :784-793

[8]

Erlichman C, 2001, CANCER RES, V61, P739

[9] Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors [J].

Erlichman, Charles ;

Hidalgo, Manuel ;

Boni, Joseph P. ;

Martins, Patricia ;

Quinn, Susan E. ;

Zacharchuk, Charles ;

Amorusi, Peter ;

Adjei, Alex A. ;

Rowinsky, Eric K. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2252-2260

[10] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

← 1 2 3 4 5 6 →